Biography of Dr. Leslie J. Browne, PhD
Dr. Browne has over thirty years of experience in the pharmaceutical industry. Prior to joining Senesco, a cancer therapeutics company focused on non-Hodgkins lymphoma and multiple myeloma and sponsoring a Phase 1b/2a clinical trial, he served as President and CEO of Phrixus Pharmaceuticals, Inc., and continues as Chair of the Board of Directors, where an IND was filed to initiate Phase 2 studies in Duchenne muscular dystrophy and heart failure. As President, CEO and Director of Pharmacopeia he transformed the company from a discovery contract research organization to a clinical development stage biopharmaceutical company with multiple internal development programs and raised over $120 million from corporate collaborations and institutional investors. He recently served as a Director of Genelabs Technologies, which was sold to GSK, and Chair of the New Jersey Technology Council. Prior to joining Pharmacopeia, Dr. Browne was the Chief Operating Officer at Iconix Pharmaceuticals, Inc., a privately-held chemogenomics company. Before Iconix Dr. Browne held key positions at Berlex/Schering AG, including Corporate Vice President, Berlex Laboratories, Inc. and President of Schering Berlin Venture Corporation. At Berlex Biosciences he rebuilt the drug discovery operation and championed a number of important pharma-biotech collaborations. Dr. Browne began his industrial career at Ciba Geigy, now Novartis, where he invented fadrozole, for the treatment of breast cancer and was closely involved in the discoveries of Femaraâ and Diovanâ, which became major products for Novartis.